ArticleJournal of managed care & specialty pharmacy2019

Implications of Removing Rosiglitazone's Black Box Warning and Restricted Access Program on the Uptake of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors Among Patients with Type 2 Diabetes.

Ryan P Hickson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.